Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

China flag China · Delayed Price · Currency is CNY
37.08
+2.98 (8.74%)
At close: Mar 10, 2026
49.34%
Market Cap 4.85B
Revenue (ttm) 619.88M
Net Income (ttm) -187.70M
Shares Out 130.89M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend 0.13 (0.38%)
Ex-Dividend Date n/a
Volume 15,848,420
Average Volume 7,262,425
Open 34.50
Previous Close 34.10
Day's Range 34.36 - 38.96
52-Week Range 19.00 - 61.76
Beta 0.31
RSI 67.20
Earnings Date Apr 24, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pec... [Read more]

Sector Healthcare
Founded 1992
Employees 1,309
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300683
Full Company Profile

Financial Performance

In 2024, SHE:300683's revenue was 648.97 million, an increase of 7.75% compared to the previous year's 602.28 million. Losses were -69.35 million, -42.60% less than in 2023.

Financial Statements

News

There is no news available yet.